Beckman Coulter Life Sciences today announced the launch of RNAdvance Viral XP, a new RNA extraction kit validated for use in infectious disease and real-time PCR virus research. The kit is now available for purchase as high-throughput laboratories worldwide ramp up RNA extraction capabilities.
RNAdvance Viral XP is intended for use in high-throughput research workflows to extract viral RNA from swab samples, an essential step in the overall workflow. After RNA extraction, the collected RNA is used in qRT-PCR kits to test whether the RNA from a virus is present, yielding a positive or negative result.
The isolation of RNA from viral samples is a critical step in researching viruses and other deadly pathogens. Our development team has worked closely with global research partners during the past several months to provide customers with a high-performing, validated viral extraction solution during this time of increased need.”
Greg Milosevich, President, Beckman Coulter Life Sciences
Beckman Coulter Life Sciences worked with iRepertoire in Huntsville, Alabama to develop the reagent kit’s method. iRepertoire then independently validated the method. Both parties were pleased with the results.
We performed more than 100 RNA extractions and more than 500 qPCR reactions during a three-day period to validate RNAdvance Viral XP. The results clearly demonstrate this new solution from Beckman Coulter Life Sciences is a viable alternative to help alleviate a critical shortage in the RNA extraction kit supply chain.
Doing our part to support customers during a time of increased need is a priority for me and all Beckman Coulter Life Sciences associates as we build a robust supply chain, scale production and increase field support capabilities. We’re all in this together, and I’m confident our technology will expand the availability of extraction solutions for research laboratories around the world.”
Miranda L. Byrne-Steele, Ph.D., Director of Operations and R&D, iRepertoire
Beckman Coulter Life Sciences is an operating company within Danaher Corporation’s Life Sciences platform.